📊 STOK Key Takeaways
Is Stoke Therapeutics, Inc. (STOK) a Good Investment?
Stoke Therapeutics demonstrates early revenue traction (+404.5% YoY) and maintains a fortress balance sheet with zero debt and $155.7M cash, but faces a critical challenge: annual operating losses of $53.4M with only ~2.5 years of cash runway at current burn rates. The company must achieve significant revenue inflection or major profitability improvements within this window, or face forced equity dilution and potential strategic alternatives.
Stoke Therapeutics, Inc. Key Strengths (STOK)
- Exceptional revenue growth (404.5% YoY) indicating product market traction
- Fortress balance sheet with zero debt, $394.9M equity, and 8.99x current ratio providing financial flexibility
- Adequate near-term liquidity (~$155.7M cash) with low leverage profile typical of well-capitalized biotech
STOK Stock Risks: Stoke Therapeutics, Inc. Investment Risks
- Severe unprofitability with -$802.7% net margin and -$60.6M annual operating cash burn limiting runway to ~2.5 years
- Limited revenue base ($6.2M) insufficient to offset operating expenses, requiring major scale-up or path to profitability is unclear
- Likely future capital dilution needed to extend runway, absent substantial revenue inflection or strategic partnerships reducing burn rate
Key Metrics to Watch
- Operating cash burn rate trend and months of cash runway remaining
- Revenue growth trajectory and gross margin as product scales
- Achievement of clinical/regulatory milestones that could trigger partnerships or reduce cash burn requirements
Stoke Therapeutics, Inc. (STOK) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 8.99x current ratio provides a solid financial cushion.
STOK Profit Margin, ROE & Profitability Analysis
STOK vs Healthcare Sector: How Stoke Therapeutics, Inc. Compares
How Stoke Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Stoke Therapeutics, Inc. Stock Overvalued? STOK Valuation Analysis 2026
Based on fundamental analysis, Stoke Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Stoke Therapeutics, Inc. Balance Sheet: STOK Debt, Cash & Liquidity
STOK Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Stoke Therapeutics, Inc.'s revenue has grown significantly by 1,387% over the 5-year period, indicating strong business expansion. The most recent EPS of $-1.65 indicates the company is currently unprofitable.
STOK Revenue Growth, EPS Growth & YoY Performance
STOK Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $6.2M | -$50.0M | $-0.79 |
| Q3 2025 | $4.9M | -$23.5M | $-0.47 |
| Q2 2025 | $4.8M | -$23.5M | $-0.40 |
| Q1 2025 | $4.2M | -$26.4M | $-0.57 |
| Q3 2024 | $3.3M | -$22.5M | $-0.47 |
| Q2 2024 | -$2.5M | -$22.5M | $-0.46 |
| Q1 2024 | $4.2M | -$22.5M | $-0.53 |
| Q3 2023 | $2.9M | -$22.5M | $-0.55 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Stoke Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
STOK SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Stoke Therapeutics, Inc. (CIK: 0001623526)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| Jun 5, 2026 | 4 | xslF345X06/form4-06052026_080612.xml | View → |
| Jun 5, 2026 | 4 | xslF345X06/form4-06052026_080637.xml | View → |
| Jun 5, 2026 | 4 | xslF345X06/form4-06052026_080631.xml | View → |
| Jun 5, 2026 | 4 | xslF345X06/form4-06052026_080620.xml | View → |
| Jun 5, 2026 | 4 | xslF345X06/form4-06052026_080652.xml | View → |
❓ Frequently Asked Questions about STOK
What is the AI rating for STOK?
Stoke Therapeutics, Inc. (STOK) has an AI grade of C with 70% confidence, based on fundamental analysis of SEC EDGAR filings.
What are STOK's key strengths?
Claude: Exceptional revenue growth (404.5% YoY) indicating product market traction. Fortress balance sheet with zero debt, $394.9M equity, and 8.99x current ratio providing financial flexibility.
What are the risks of investing in STOK?
Claude: Severe unprofitability with -$802.7% net margin and -$60.6M annual operating cash burn limiting runway to ~2.5 years. Limited revenue base ($6.2M) insufficient to offset operating expenses, requiring major scale-up or path to profitability is unclear.
What is STOK's revenue and growth?
Stoke Therapeutics, Inc. reported revenue of $6.2M.
Does STOK pay dividends?
Stoke Therapeutics, Inc. does not currently pay dividends.
Where can I find STOK SEC filings?
Official SEC filings for Stoke Therapeutics, Inc. (CIK: 0001623526) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is STOK's EPS?
Stoke Therapeutics, Inc. has a diluted EPS of $-0.79.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is STOK's fundamental grade?
Based on our AI fundamental analysis in June 2026, Stoke Therapeutics, Inc. has a C grade with 70% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is STOK stock overvalued or undervalued?
Valuation metrics for STOK: ROE of -12.7% (sector avg: 15%), net margin of -802.7% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is STOK's AI grade for 2026?
Our dual AI analysis gives Stoke Therapeutics, Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is STOK's free cash flow?
Stoke Therapeutics, Inc.'s operating cash flow is $-60.6M, with capital expenditures of $353.0K. FCF margin is -978.2%.
How does STOK compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -802.7% (avg: 12%), ROE -12.7% (avg: 15%), current ratio 8.99 (avg: 2).